Gilead

top of page

HIV TREATMENT

2020

Pharmaceutical companies, SRAs, WHO Prequalification Programme (PQ) and NRAs commit to:

Action 27. Mobilize their networks and work with communities to help build treatment literacy, generate demand, and expand access to ARVs among children.

Action 34. Increase efforts to share information on the roll-out of new paediatric formulations, including lessons learned.

Paediatric HIV & TB : Rome Action Plan

INDIVIDUAL COMMITMENTS

Gilead

Gilead committed to having clinical data ready for a low-dose TAF based regimen for children 2-12 years by late 2018/early 2019.

Committed by:

Sub-Actions & Milestones

Sub-action Gilead.1

Having clinical data ready for a low-dose TAF based regimen for children 2-12 years by late 2018/early 2019.

Milestone Gilead.1.1

Document (s)

Updates

Notes

Responsible

bottom of page